NASDAQ:ALIM
Alimera Sciences Stock News
$3.49
+0.180 (+5.44%)
At Close: Apr 26, 2024
Why Fast-paced Mover Alimera Sciences (ALIM) Is a Great Choice for Value Investors
10:32am, Monday, 29'th Aug 2022
Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stock
Alimera Sciences (ALIM) Is a Great Choice for "Trend" Investors, Here's Why
12:50pm, Friday, 19'th Aug 2022 Zacks Investment Research
Alimera Sciences (ALIM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it thr
Alimera Sciences (ALIM) Is a Great Choice for "Trend" Investors, Here's Why
10:32am, Friday, 19'th Aug 2022
Alimera Sciences (ALIM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it thr
Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year?
01:40pm, Wednesday, 17'th Aug 2022 Zacks Investment Research
Here is how Alimera Sciences (ALIM) and Centene (CNC) have performed compared to their sector so far this year.
Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year?
11:17am, Wednesday, 17'th Aug 2022
Here is how Alimera Sciences (ALIM) and Centene (CNC) have performed compared to their sector so far this year.
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
12:00pm, Wednesday, 10'th Aug 2022 GlobeNewswire Inc.
ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partne
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
08:00am, Wednesday, 10'th Aug 2022
ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners
Here Is Why Bargain Hunters Would Love Fast-paced Mover Alimera Sciences (ALIM)
12:50pm, Friday, 05'th Aug 2022 Zacks Investment Research
Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stock
Here Is Why Bargain Hunters Would Love Fast-paced Mover Alimera Sciences (ALIM)
10:32am, Friday, 05'th Aug 2022
Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stock
Has Alimera Sciences (ALIM) Outpaced Other Medical Stocks This Year?
01:40pm, Monday, 01'st Aug 2022 Zacks Investment Research
Here is how Alimera Sciences (ALIM) and Eli Lilly (LLY) have performed compared to their sector so far this year.
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2022 Results - Earnings Call Transcript
08:23am, Saturday, 30'th Jul 2022
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q2 2022 Earnings Conference Call July 27, 2022 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
12:45pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 26.23% and 8.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update
02:34pm, Friday, 22'nd Jul 2022 GlobeNewswire Inc.
Conference Call to be held Wednesday July 27, at 9:00am Eastern Time Conference Call to be held Wednesday July 27, at 9:00am Eastern Time
Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France
12:00pm, Friday, 22'nd Jul 2022 GlobeNewswire Inc.
Partner Horus Pharma to launch ILUVIEN for non-infectious uveitis affecting the posterior segment indication later in Q3 Partner Horus Pharma to launch ILUVIEN for non-infectious uveitis affecting the
Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update
10:34am, Friday, 22'nd Jul 2022
Conference Call to be held Wednesday July 27, at 9:00am Eastern Time Conference Call to be held Wednesday July 27, at 9:00am Eastern Time
